SK Bioscience Co Ltd
KRX:302440
SK Bioscience Co Ltd
KRX:302440
Price:
43 850
KRW
3.91%
Market Cap:
₩3.4T
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
SK Bioscience Co Ltd
KRX:302440
|
KR |
|
AddLife AB
STO:ALIF B
|
SE |
Balance Sheet
Balance Sheet Decomposition
SK Bioscience Co Ltd
SK Bioscience Co Ltd
Balance Sheet Decomposition is not available for
SK Bioscience Co Ltd
SK Bioscience Co Ltd
Balance Sheet
SK Bioscience Co Ltd
SK Bioscience Co Ltd
Currency: KRW
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
4 489
|
14 380
|
24 972
|
98 028
|
225 287
|
127 026
|
312 700
|
105 553
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
4 489
|
14 380
|
24 972
|
98 028
|
225 287
|
127 026
|
312 700
|
105 553
|
|
| Short-Term Investments |
99 189
|
80 088
|
183 736
|
1 547 635
|
1 250 218
|
1 141 816
|
843 807
|
799 148
|
|
| Total Receivables |
43 472
|
32 429
|
54 008
|
48 135
|
89 661
|
22 342
|
188 396
|
132 943
|
|
| Accounts Receivables |
42 873
|
32 241
|
31 476
|
39 027
|
41 059
|
18 235
|
105 894
|
123 700
|
|
| Other Receivables |
599
|
188
|
22 532
|
9 107
|
48 602
|
4 108
|
82 502
|
9 243
|
|
| Inventory |
31 876
|
36 378
|
70 275
|
135 046
|
187 406
|
80 649
|
211 126
|
189 203
|
|
| Other Current Assets |
1 703
|
7 465
|
911
|
8 960
|
31 122
|
11 136
|
20 643
|
19 278
|
|
| Total Current Assets |
180 729
|
170 741
|
333 902
|
1 837 804
|
1 783 694
|
1 382 969
|
1 576 673
|
1 246 125
|
|
| PP&E Net |
172 831
|
190 770
|
189 479
|
220 983
|
293 057
|
315 923
|
982 607
|
1 130 387
|
|
| Intangible Assets |
21 839
|
19 479
|
17 858
|
17 061
|
18 181
|
22 459
|
67 112
|
138 708
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
57 436
|
55 253
|
|
| Note Receivable |
10 985
|
10 597
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
86
|
86
|
86
|
586
|
1 586
|
42 815
|
29 115
|
242 254
|
|
| Other Long-Term Assets |
13 528
|
12 307
|
20 907
|
33 688
|
45 413
|
88 273
|
130 653
|
143 016
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
57 436
|
55 253
|
|
| Total Assets |
399 997
N/A
|
403 980
+1%
|
562 232
+39%
|
2 110 123
+275%
|
2 141 931
+2%
|
1 852 439
-14%
|
2 843 596
+54%
|
2 955 744
+4%
|
|
| Liabilities | |||||||||
| Accounts Payable |
11 077
|
18 372
|
17 505
|
63 812
|
11 053
|
3 370
|
17 818
|
35 287
|
|
| Accrued Liabilities |
4 550
|
7 094
|
11 520
|
26 322
|
30 242
|
19 716
|
54 298
|
52 639
|
|
| Short-Term Debt |
0
|
0
|
0
|
11 671
|
45 550
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
11 411
|
1 351
|
12 608
|
50 287
|
50 243
|
8 137
|
6 957
|
3 753
|
|
| Other Current Liabilities |
23 572
|
18 692
|
139 006
|
307 860
|
242 949
|
104 397
|
231 518
|
234 559
|
|
| Total Current Liabilities |
50 610
|
45 509
|
180 639
|
459 952
|
380 037
|
135 620
|
310 589
|
326 238
|
|
| Long-Term Debt |
126 550
|
123 721
|
109 359
|
44 277
|
17 543
|
12 436
|
385 857
|
466 235
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
71 960
|
64 036
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
219 887
|
248 654
|
|
| Other Liabilities |
3 592
|
2 015
|
8 443
|
4 581
|
2 649
|
528
|
52 737
|
61 780
|
|
| Total Liabilities |
180 751
N/A
|
171 246
-5%
|
298 442
+74%
|
508 811
+70%
|
400 229
-21%
|
148 584
-63%
|
1 041 031
+601%
|
1 166 944
+12%
|
|
| Equity | |||||||||
| Common Stock |
10 200
|
10 200
|
30 600
|
38 250
|
38 392
|
38 414
|
39 174
|
39 217
|
|
| Retained Earnings |
9 043
|
22 308
|
53 236
|
405 305
|
533 378
|
549 421
|
499 757
|
445 262
|
|
| Additional Paid In Capital |
201 245
|
201 545
|
181 419
|
1 157 064
|
1 160 008
|
1 160 456
|
1 235 376
|
1 236 272
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
54 727
|
6 652
|
4 901
|
|
| Other Equity |
1 242
|
1 319
|
1 465
|
693
|
9 924
|
10 292
|
21 606
|
63 148
|
|
| Total Equity |
219 246
N/A
|
232 734
+6%
|
263 790
+13%
|
1 601 312
+507%
|
1 741 702
+9%
|
1 703 855
-2%
|
1 802 565
+6%
|
1 788 800
-1%
|
|
| Total Liabilities & Equity |
399 997
N/A
|
403 980
+1%
|
562 232
+39%
|
2 110 123
+275%
|
2 141 931
+2%
|
1 852 439
-14%
|
2 843 596
+54%
|
2 955 744
+4%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
61
|
61
|
61
|
77
|
77
|
77
|
78
|
78
|
|
Switch to:
Switch to:
See Also
Discover More
